LifeMD

LifeMD reported Q1 2026 results today — a strong start to the year. • Revenue of $50.2M, exceeding guidance • 42,000+ net new telehealth subscribers; the largest quarterly net add in our history • Gross margin expanded ~420 bps to 88% "LifeMD is no longer just a telehealth company focused on a handful of conditions. We are building what we believe can become one of the most important virtual healthcare platforms in the country — a trusted destination where patients can access care, medications, labs, insurance-supported services, and ongoing clinical support through one connected experience." — Justin Schreiber, Chairman & CEO Full release: https://lnkd.in/geGWdapt

Our 2026 shareholder letter is live. 322k+ active patients across all 50 states. Telehealth revenue of $194M in 2025, targeting a $250M annualized run rate by year end. Strategic collaborations with Eli Lilly and Novo Nordisk. And a growing Women's Health program we're incredibly proud of. Read the full letter from our Chairman & CEO, Justin Schreiber: https://lnkd.in/e3ftbVbP

LifeMD is now offering Foundayo™ (orforglipron) — Eli Lilly and Company's newly FDA-approved once-daily GLP-1 pill for weight management. Through our integration with LillyDirect®, eligible LifeMD patients can access Foundayo starting at $149/month, with eligible commercially insured patients potentially paying as little as $25/month. Foundayo is available through LifeMD's comprehensive weight management program, which pairs medication access with virtual clinician consultations, diagnostic testing, and personalized support. We continue to expand our branded GLP-1 offerings across both Lilly and Novo Nordisk, with one goal: making clinically guided, evidence-based weight management accessible to more Americans. Read more here: https://lnkd.in/gVy-3WRt #LifeMD #Foundayo #Orforglipron #EliLilly #GLP1 #ObesityMedicine

We are thrilled to welcome Atul Kavthekar as our new Chief Financial Officer. Atul is a seasoned financial executive with nearly three decades of leadership experience spanning provider-side healthcare, specialty pharmacy, e-commerce, and technology. At LifeMD, he will focus on building the financial and operational infrastructure to support the Company's continued growth and long-term value creation. A technology and AI enthusiast with an engineering background, Atul will also work alongside LifeMD's technology team to advance the Company's vision of becoming an AI-first healthcare company. We are also proud to announce that Chris Pisano has been appointed Chief Marketing Officer, overseeing marketing communications, digital marketing, and market positioning, while driving cross-selling initiatives and engagement strategies that deepen the patient relationship. Additionally, Jessica Friedeman has been named Chief Business Officer, spearheading the launch of LifeMD’s enterprise and employer health offerings, while continuing to serve as General Manager of LifeMD’s comprehensive women’s health division. Please join us in welcoming Atul and congratulating Jessica and Chris — we are excited about what this team will accomplish as LifeMD enters its next phase of growth! https://lnkd.in/ewDKuT7C

We’re excited to share that LifeMD is now offering Novo Nordisk’s newly FDA-approved Wegovy® pill — the first and only oral GLP-1 therapy for chronic weight management and cardiovascular health — through our end-to-end telehealth platform. This milestone expands our long-standing collaboration with Novo Nordisk, with LifeMD recognized as a recommended telehealth partner on NovoCare® and Wegovy® websites. Eligible patients can access the Wegovy® pill starting at $149/month, broadening access to branded, FDA-approved obesity treatments without injections. As demand for GLP-1 therapies continues to grow, we remain focused on delivering convenient, clinically supported, and affordable care — from virtual visits and ongoing medical oversight to fast, coordinated pharmacy fulfillment shipped directly to patients’ homes. Read the full announcement: https://lnkd.in/e5GBPWxD #LifeMD #NovoNordisk #Wegovy #GLP1 #Telehealth #ObesityCare

LifeMD is proud to be recognized on Deloitte’s 2025 Technology Fast 500™ and TIME’s inaugural America’s Growth Leaders of 2026 list! These accolades are a direct reflection of LifeMD’s continued revenue growth, financial stability, and emerging leadership in the health tech sector. We are excited to continue expanding our impact on the lives of our patients and creating long-term value for our shareholders as we close out the year! https://lnkd.in/ehFFh4VF

LifeMD Announces Lowest Cash-Pay Pricing for Wegovy® & Ozempic® We are proud to offer market-leading $199/month pricing for .25 mg and .5 mg doses of Wegovy® and Ozempic®, made possible through our continued collaboration with Novo Nordisk. This is the lowest cash-pay pricing available nationwide for new patients. These medications are available through the LifeMD Weight Management Program, which includes virtual visits, diagnostic testing, secure messaging, and metabolic health support. This announcement aligns with national efforts to expand access to GLP-1 therapies and reflects our commitment to making safe, FDA-approved treatments more affordable. Learn more about this exciting announcement here: https://lnkd.in/ebTZrhyN

Today, LifeMD announced the sale of its majority ownership interest in WorkSimpli Software. This transaction marks a significant milestone in our strategic transformation, reinforcing LifeMD’s position as a pure-play healthcare company focused solely on expanding our virtual care and pharmacy services. We would also like to congratulate WorkSimpli's founder and CEO, Sean Fitzpatrick, and his team for their dedication and hard work. For more details, visit our Investor Relations website https://lnkd.in/eSMwJ3-m

We’re thrilled to welcome Dr. Tara Scott—nationally recognized as “The Hormone Guru”—as the new Ambassador and Clinical Advisor for LifeMD’s Women’s Health Program! Dr. Scott brings over 25 years of clinical, research, and teaching experience in women’s health, hormone therapy, and integrative medicine. As a board-certified OB/GYN, certified menopause practitioner, and passionate advocate for women’s wellness, she’s spent her career helping women take charge of their health through evidence-based, personalized care. At LifeMD, we’re building one of the most thoughtful and comprehensive virtual health programs for women—one that addresses perimenopause, menopause, hormonal balance, bone health, metabolism, and long-term wellness. With Dr. Scott’s guidance, we’re doubling down on our commitment to: ✅ Deliver virtual consultations rooted in clinical expertise and lifestyle-focused care ✅ Expand access to hormone therapy, lab testing, prescription fulfillment, and dietitian support ✅ Support women at every stage with 24/7 access to care and an ecosystem of curated wellness tools This appointment marks a major milestone in our mission to close the care gap for women and build a future where their unique needs are not only recognized—but prioritized. 🔗 Learn more about our program at www.lifemd.com #LifeMD #WomensHealth #Telehealth #Menopause #HormoneHealth #VirtualCare #HealthcareInnovation #DigitalHealth #MenopauseCare #WomensWellness

We’re expanding our collaboration with Novo Nordisk! Through LifeMD’s seamless integration with NovoCare® Pharmacy, eligible patients can now access all FDA-approved dose strengths of Ozempic® for just $499/month. Millions of Americans living with type 2 diabetes still struggle with coverage gaps for GLP-1 therapies. This is another step toward helping remove barriers to authentic, FDA-approved treatments at the most competitive cash-pay prices on the market—while delivering a seamless, clinically supported patient experience from prescription to fulfillment. Read more about our work with Novo Nordisk to improve access for patients and strengthen outcomes nationwide. https://lnkd.in/egKrCJMP #lifemd #NovoNordisk #Ozempic #Telehealth #VirtualCare #DiabetesCare